

एयु स्मॉल फायनान्स बँक लिमिटेड (शेड्युल्ड कमर्शियल बँक)
नॉ. कार्यालय : १९-ए, धुळेखर गाईन, अजमेर रोड, जयपूर - ३०२००१ (सीआयएन : एल३६१११आरजे१९६६एपीएसी०११३८१)

परिशिष्ट IV (नियम ८(1) पहा) कब्जा सूचना

ज्याअर्थी निम्नवर्गीकरांनी एयु स्मॉल फायनान्स बँक लिमिटेड (शेड्युल्ड कमर्शियल बँक) चे प्राधिकृत अधिकारी म्हणून सिम्बुटियायझेशन अँड रिक्स्ट्रक्शन ऑफ फायनान्सियल असेट्स अँड एफोर्समेंट ऑफ लिक्विडिटी इस्टेट (अँड, २००२ (१४ सन २००२) अन्वये आणि लिक्विडिटी इस्टेट (एफोर्समेंट) कलम २००२ च्या नियम ३ सहवाचता कलम १३(१२) अन्वये प्रदान केलेल्या अधिकारांचा वापर करून खाती कोटकातयेवढे दिलेला तपशीलाप्रमाणे सदर सूचना प्राप्त झाल्यापासून ६० दिवसांत सूचित नमुद केलेली रक्कम प्रदान करण्यासाठी कर्जदारांना बोलावण्याकरिता खालील नमुद तारखेची मागणी सूचना जारी केलेली आहे.

कर्जदार/सह-कर्जदार/गहाणवटदार/रप्रीदादाचे नाव/कर्ज खाते क्र.	१३(२) सूचनेची तारीख आणि रकम	गहाण मिळकतीचे वर्णन	कब्जा घेतल्याची तारीख
(कर्ज खाते क्र.) एल२००१०६०७३८१९६१९६, मे. सुनील प्रॉब्लिज अँड ज्वेल स्टोअर (कर्जदार), सुनील मेश विजयगरे (सह-कर्जदार), रमेश शंकरराव विजयगरे (सह-कर्जदार)	२१-मे-२५ रु. २३,८०,३२५/- रु. तेव्हास लाख एंजी हजारा तीसो पंचवीस मात्र १३-मे-२५ रोजीस	निवासी/कमर्शियल मिळकत जमिन/विल्डिंग/रचना आणि फिक्स्चर चे ते सर्व भाग आणि विभाग (मिळकत क्र.१) मिळकत येथे स्थित शां.०१, नवुल प्लॉट क्र.०२, शां. क्र. २०, सी कसबा - अकोट, जिल्हा अकोला, महाराष्ट्र मोजमापित १४.८८ चौ.गज पूर्व - क्षेत्रफळ १४.८८ चौ. गज, पूर्वेस डॉ. इमारे यांचे घर, पश्चिमेस शिणकर यांचे दुकान, उत्तरेस सरकारी रस्ता, दक्षिणेस शिणकर यांचे घर, (मालमत्ता क्र. २) ही मालमत्ता पूर्व-पश्चिम विभागातील उत्तरीकडील बाजूस असलेल्या लेआउट प्लॉट क्र. ०३, फ्लॅट सर्व्हे क्र. २०/२, कासबे अकोट, जिल्हा अकोला, महाराष्ट्र येथे स्थित आहे. क्षेत्रफळ १०९.५ चौ. गज, पूर्वेस सर्व्हे क्र. २१, पश्चिमेस ६ मीटर रस्ता, उत्तरेस लेआउट प्लॉट क्र. ०४, दक्षिणेस त्याचा प्लॉटचा उर्वरित भाग.	०६-नोव्हेंबर-२५
(कर्ज खाते क्र.) एल२००१०६०७३८१९६१९६०, मे. स्पॅम एंटरप्राइजेस (कर्जदार), पंढरीनाथ महादू पटारे (सह-कर्जदार), राजेश महादू पटारे (सह-कर्जदार), प्राकाश पंढरीनाथ महादू (सह-कर्जदार)	१९-जून-२५ रु. २०,१४,६२१/- रु. वीस लाख अकरा हजार सहाशे एकवीस मात्र १२-जून-२५ रोजीस	निवासी/कमर्शियल मिळकत जमिन/विल्डिंग/रचना आणि फिक्स्चर चे ते सर्व भाग आणि विभाग मिळकत येथे स्थित सर्व्हे क्र. २/२, १०/२, १०/३, १०/४, ११/२, हाऊस क्र. १५५, गाव कलांबे आणि निशेत, ता. वाडा, जिल्हा पालघर, महाराष्ट्र मोजमापित १५९६ चौ. फू. पूर्व: निशेत गाव, पश्चिम: ओपन प्लॉट, उत्तर: ओपन प्लॉट, दक्षिण: निशेत गाव	०७-नोव्हेंबर-२५

कर्जदारांनी घट्ट रक्कम प्रदान करण्यास कसू केलेली आहे म्हणून याद्वारे कर्जदार आणि सर्वसामान्य जनतेला सूचना देण्यात येत आहे की, निम्नवर्गीकरांनी वरील कोटकात नमुद केलेल्या तारखेस सदर (अँड २००२) चे कलम १३(४) सहवाचता सदर नियमावलीच्या नियम ८ अन्वये त्यांना/तिला प्रदान केलेल्या अधिकारांचा वापर करून येथील वरील नमुद कोटकात नमुद केलेल्या मिळकतीचा कब्जा घेतला आहे. "कर्जदारांचे लक्ष ताणू मत्ता विमोचनसाठी उपलब्ध वेळेच्या संदर्भात म्हणजेच या सूचनेपासून ३० दिवसांत अधिनियमाच्या कलम १३ च्या पोट कलम (८) सहवाचता नियम ८(६) च्या तरतुदीकडे वेधण्यात येत आहे".

विशेषतः कर्जदार आणि सर्वसामान्य जनतेला याद्वारे सावधान करण्यात येते की, सदर मिळकतीच्या देवघेवीचा व्यवहार करू नये आणि सदर मिळकतीच्या देवघेवीचा कोणताही व्यवहार हा वरील कोटकात नमुद केलेली रक्कम आणि त्यावरील व्याज या रकमेकरिता एयु स्मॉल फायनान्स बँक लिमिटेड (शेड्युल्ड कमर्शियल बँक) च्या प्रभारानेच अधीन राहिले.

दिनांक : ११/११/२०२५ ठिकाण: मुंबई प्राधिकृत अधिकारी, एयु स्मॉल फायनान्स बँक लिमिटेड

RELIANCE Infrastructure

रिलायन्स इन्फ्रास्ट्रक्चर लिमिटेड
सीआयएन: एल२५१००एमएच१९२११एएसी०१५३०
मॉदीप्रीकृत कार्यालय: रिलायन्स सेंटर, तळ मजला, १९, बालचंद्र हिरोचंद मार्ग, बलाई इस्टेट, मुंबई-४०० ००१. फ़: ९१ २२ ४३०३१०००
वेबसाईट: www.rinfra.com, ईमेल: rinfra.investors@reliancegroupindia.com

सप्टेंबर ३०, २०२५ रोजी संपलेली तिमाही आणि अर्ध वर्षासाठी अलेखापरिक्षित वित्तीय निष्कर्ष (अलिप्त आणि एकात्रित) चे विवरण

नोव्हेंबर ११, २०२५ रोजी झालेल्या सभेमध्ये कंपनीचे संचालक मंडळाने सप्टेंबर ३०, २०२५ रोजी संपलेली तिमाही आणि अर्ध वर्षासाठी कंपनीच्या अलेखापरिक्षित वित्तीय निष्कर्ष ("वित्तीय निष्कर्ष") ला मंजुरी दिली. वित्तीय निष्कर्ष सह मर्यादित पूनरावलोकन अहवाल www.rinfra.co.in येथे कंपनीची वेबसाईट आणि स्टॉक एक्सचेंजेसची वेबसाईट www.bseindia.com आणि www.nseindia.com वर टाकलेले आहे आणि तसेच ह्या क्यूआर कोड स्कॅन करून सदर मिळवता येईल.

ठिकाण: मुंबई
दिनांक: नोव्हेंबर ११, २०२५



रिलायन्स इन्फ्रास्ट्रक्चर लिमिटेडचे संचालक मंडळाकरिता आणि च्यावतीने सही/- विजेश बाबू थोटा कार्यकारी संचालक आणि सीएफओ

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Registered Office: 'B' Wing, Neelam Centre, 4th Floor, Hind Cycle Road, Worli, Mumbai, Maharashtra - 400 030.
Corporate Identification Number: L24390MH1976PLC019390
Tel. No.: +91 22-2439 5200/5500; Website: <http://www.jbpharma.com/>

Recommendations of the Committee of Independent Directors ("IDC") of J.B. Chemicals & Pharmaceuticals Limited ("Target Company") on the Open Offer (as defined below) made by Torrent Pharmaceuticals Limited ("Acquirer") to the Eligible Shareholders (as defined in the letter of offer dated November 6, 2025) of the Target Company, under Regulation 26(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations").

1.	Date	November 11, 2025
2.	Name of the Target Company (TC)	J.B. Chemicals & Pharmaceuticals Limited
3.	Details of the Offer pertaining to TC	Open offer for acquisition of up to 4,17,45,264 (four crore seventeen lakh forty five thousand two hundred and sixty four) fully paid-up equity shares of the Target Company, having face value of INR 1 (Indian Rupee one only) each ("Equity Shares"), representing 26.00% of the Expanded Share Capital (as defined in the letter of offer dated November 6, 2025), at a price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share ("Offer Price"), from the Eligible Shareholders of the Target Company ("Open Offer"). The public announcement dated June 29, 2025 ("PA"), the detailed public statement published on July 04, 2025 ("DPS"), the draft letter of offer dated July 11, 2025 ("DLOF"), the corrigendum to the PA, DPS and DLOF published on September 4, 2025 ("Corrigendum") and the letter of offer dated November 6, 2025 ("LOF") have been issued by NovaaOne Capital Private Limited, the manager to the Open Offer ("Manager"), on behalf of the Acquirer.
4.	Name(s) of the acquirer and PAC with the acquirer	Torrent Pharmaceuticals Limited is the Acquirer. Basis a review of the PA, DPS, DLOF, Corrigendum and the LOF issued by the Manager to the Offer on behalf of the Acquirer (together, the "Open Offer Documents"), the IDC notes that there are no persons acting in concert (PACs) with the Acquirer for the purposes of the Open Offer.
5.	Name of the Manager to the offer	NovaaOne Capital Private Limited, Address: Tower 2A, Floor 9, One World Centre, Lower Parel, Mumbai, 400013. Contact Person: Dhruv Bhatia, Tel. No.: +91-22-62466000. Email: jb_openoffer@novaaone.com, SEBI Registration Number: INM000012935
6.	Members of the Committee of Independent Directors (Please indicate the chairperson of the Committee separately)	(a) Mr. Arun Duggal, Chairman. (b) Mr. Sumit Bose. (c) Mr. Ashwani Kumar Puri. (d) Ms. Richa Arora.
7.	IDC Member's relationship with the TC (Director, Equity shares owned, any other contract / relationship), if any	All the members of the IDC are independent directors on the board of directors of the Target Company. None of the IDC members hold any Equity Shares/ securities of the Target Company or have entered into any other contract/ relationship with the Target Company, except as directors on the board of directors of the Target Company and as members of the board committees.
8.	Trading in the Equity shares/ other securities of the TC by IDC Members	None of the members of the IDC have traded in any of the Equity Shares/ securities of the Target Company during the: (a) 12 (twelve) month period preceding the date of the PA; and (b) period from the date of the PA and till the date of this recommendation.
9.	IDC Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any.	None of the members of the IDC: (a) are directors on the board of directors of the Acquirer; (b) hold any equity shares or other securities of the Acquirer; and (c) have any contracts/ relationship with the Acquirer.
10.	Trading in the Equity shares/ other securities of the acquirer by IDC Members	None of the members of the IDC have traded in any of the Equity Shares/ securities of the Acquirer during the: (a) 12 (twelve) month period preceding the date of the PA; and (b) period from the date of the PA and till the date of this recommendation.
11.	Recommendation on the Open offer, as to whether the offer is fair and reasonable	The IDC has perused the Open Offer Documents and the certificate dated June 29, 2025, issued by G. K. Choksi & Co., Chartered Accountants which, <i>inter alia</i> , sets out the calculation of the Offer Price taking June 27, 2025 as the reference date (i.e. the working day prior to the date of the PA, since the PA was issued on a non-working day) as per the applicable regulations of the SEBI (SAST) Regulations. The IDC has also noted that the Offer Price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share has been determined in terms of Regulations 8(1) and 8(2) of the SEBI (SAST) Regulations being the highest of various parameters mentioned therein. Basis the above, IDC notes that the Offer Price of INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share has been determined by taking June 27, 2025 as the reference date (i.e. the working day prior to the date of the PA, since the PA was issued on a non-working day) in accordance with the applicable regulations of the SEBI (SAST) Regulations and accordingly, is of the opinion that the Offer Price is fair and reasonable.
12.	Summary of reasons for recommendation	The IDC has perused the Open Offer Documents and the certificate dated June 29, 2025, issued by G. K. Choksi & Co., Chartered Accountants, certifying the computation of the Offer Price and has considered the following reasons for making the recommendation in paragraph 11 above: (a) The Offer Price is higher than the negotiated price for acquisition of Equity Shares by the Acquirer under the share purchase agreements, i.e., INR 1,600 (Indian Rupees one thousand six hundred only) per Equity Share; (b) The Offer Price is equal to the volume-weighted average market price of the Equity Shares during the period of 60 (sixty) trading days immediately preceding the date of the PA (i.e., from April 1, 2025 to June 27, 2025), as traded on the National Stock Exchange of India Limited (the stock exchange with maximum volume of trading during such period), i.e., INR 1,639.18 (Indian Rupees one thousand six hundred thirty nine and eighteen paise only) per Equity Share; and (c) The Offer Price (being the highest price prescribed amongst the selective criteria) has been determined in accordance with Regulation 8(2) of the SEBI (SAST) Regulations. However, the members of the IDC draw attention of the Eligible Shareholders to the closing market price of the Equity Shares on the National Stock Exchange of India Limited and BSE Limited as on November 10, 2025, being INR 1,813.30 (Indian Rupees one thousand eight hundred thirteen and thirty paise only) per Equity Share and INR 1,813.40 (Indian Rupees one thousand eight hundred thirteen and forty paise only) per Equity Share, respectively, which is higher than the Offer Price. The Eligible Shareholders of the Target Company are advised to independently evaluate the Open Offer and the market performance of the Target Company's scrip and take an informed decision about tendering the Equity Shares held by them in the Open Offer. This statement of recommendation will be available on the website of the Target Company at www.jbpharma.com
13.	Disclosure of the Voting Pattern	The recommendations were unanimously approved by the members of IDC.
14.	Details of Independent Advisors, if any	AZB & Partners (legal advisors).
15.	Any other matter(s) to be highlighted	None.

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respects, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations.

For and on behalf of the Committee of Independent Directors of J.B. Chemicals & Pharmaceuticals Limited:

Sd/-
Arun Duggal
Chairman of Committee of Independent Directors
DIN - 00024262

Place : Gurugram
Date : November 11, 2025

Ideas Create, Values Protect

Consolidated financial results for the quarter and half year ended 30 September 2025

(₹ in Crores)

Particulars	Quarter ended			Half year ended		Year ended March 31, 2025 (Audited)
	September 30, 2025 (Reviewed)	June 30, 2025 (Reviewed)	September 30, 2024 (Reviewed)	September 30, 2025 (Reviewed)	September 30, 2024 (Reviewed)	
1 Total income from operations	1,899.77	2,281.08	2,842.26	4,180.85	5,178.83	9,518.71
2 Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(46.27)	110.39	319.31	64.12	424.01	801.62
3 Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(46.27)	110.39	319.31	64.12	424.01	801.62
4 Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	175.45	102.69	137.02	278.14	222.32	535.82
5 Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(59.47)	(49.47)	239.25	(108.94)	282.51	(237.32)
6 Paid-up equity share capital (Face Value of ₹ 1/- Per Share)	94.61	93.95	91.88	94.61	91.88	92.14
7 Reserves (excluding Revaluation Reserves)						5,515.56
8 Earnings Per Share (EPS) in Rupees (Face Value of ₹ 1/- Per Share)						
- Basic (Not annualised)	1.86	1.10	1.52	2.97	2.47	5.89
- Diluted (Not annualised)	1.85	1.10	1.51	2.94	2.46	5.81

Notes:

- The above is an extract of the detailed format of quarter and half year ended consolidated financial results filed with Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of consolidated financial results are available on the website of Stock Exchanges (www.bseindia.com and www.nseindia.com) and the Company's website (www.edelweissfin.com).
- The consolidated financial results of Edelweiss Financial Services Limited ("EFSL" or 'the Company') and its subsidiaries and trusts (together referred as 'Group') for the quarter and half year ended 30 September 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 November 2025.
- The consolidated financial results of the Company for the quarter and half year ended 30 September 2025 have been subjected to review by the Statutory Auditors of the Company and the auditors have issued an unmodified review report.

Standalone financial results for the quarter and half year ended 30 September 2025

(₹ in Crores)

Particulars	Quarter ended			Half year ended		Year ended March 31, 2025 (Audited)
	September 30, 2025 (Reviewed)	June 30, 2025 (Reviewed)	September 30, 2024 (Reviewed)	September 30, 2025 (Reviewed)	September 30, 2024 (Reviewed)	
1 Total income from operations	122.12	166.80	150.35	288.92	124.91	383.41
2 Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	2.71	70.46	28.77	73.17	(89.03)	(54.26)
3 Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	2.71	70.46	28.77	73.17	(89.03)	(54.26)
4 Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	32.83	65.34	29.17	98.17	(59.49)	(51.91)
5 Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	32.58	65.09	29.17	97.67	(59.49)	(53.10)
6 Paid-up equity share capital (Face Value of ₹ 1/- Per Share)	94.61	93.95	91.88	94.61	91.88	92.14
7 Reserves (excluding Revaluation Reserves)						5,424.95
8 Earnings Per Share (EPS) in Rupees (Face Value of ₹ 1/- Per Share)						
- Basic (Not annualised)	0.35	0.70	0.32	1.05	(0.66)	(0.57)
- Diluted (Not annualised)	0.35	0.70	0.32	1.04	(0.66)	(0.56)

Notes:

- The above is an extract of the detailed format of quarter and half year ended standalone financial results filed with Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of standalone financial results are available on the website of Stock exchange (www.bseindia.com and www.nseindia.com) and the Company's website (www.edelweissfin.com).
- The standalone financial results of Edelweiss Financial Services Limited ("EFSL" or 'the Company') for the quarter and half year ended 30 September 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 November 2025.
- The standalone financial results of the company for the quarter and half year ended 30 September 2025 have been subjected to review by the Statutory Auditors of the Company and the auditors have issued an unmodified review report.



On behalf of the Board of Directors

Rashesh Shah
Chairman
DIN: 00008322

Mumbai, 11 November 2025



Home Loans | Insurance | Business Loans | Asset Management | Wealth Management

Edelweiss Financial Services Limited

CIN: L99999MH1995PLC094641, Regd. Office: Edelweiss House, Off. CST Road, Kalina, Mumbai - 400 098
Tel: +91-22-4009 4400 Fax: +91-22-4086 3610 Website : www.edelweissfin.com